September 26, 2025 – Asian equity markets tumbled on Friday, with pharmaceutical shares leading losses after U.S. President Donald Trump announced a 100% import tariff on all branded or patented pharmaceutical products, effective October 1. The measure exempts companies that have already begun building or are currently constructing manufacturing facilities in the United States, according to a post on Trump’s Truth Social account.

This marks one of the most aggressive steps yet in Washington’s protectionist trade agenda, with potentially far-reaching implications for the global pharmaceutical industry.

Asian Markets React Sharply

In Japan, the Topix Pharma Index fell 1.39%. Major drugmakers led the declines, with Daiichi Sankyo down 3.34%, Chugai Pharmaceutical sliding 2.18%, and Sumitomo Pharma losing 3.03%. All three firms derive a significant portion of revenue from the U.S. market.

In South Korea, selling pressure was equally pronounced. Biotechnology giant Samsung Biologics dropped 1.66%, while SK Bio Pharmaceuticals fell 2.66%.

In Hong Kong, pharmaceutical names were among the worst performers on the Hang Seng Index. Wuxi Biologics led losses, shedding 2.95%, followed by Alibaba Health Information Technology (-1.84%) and Sino Biopharmaceutical (-1.25%).

The widespread declines reflect investor concerns that steep tariffs will erode profits for companies heavily reliant on U.S. pharmaceutical sales still the world’s largest drug market.

Broader Tariff Measures Across Sectors

The tariff escalation extended well beyond pharmaceuticals. In a separate Truth Social post, Trump announced that:

• Heavy-duty trucks will face a 25% tariff.

• Kitchen cabinets, bathroom vanities, and related products will be subject to a 50% tariff.

• Upholstered furniture will carry a 30% tariff.

The move underscores Washington’s intent to deepen protection across multiple industries, while pressuring multinational corporations to relocate manufacturing to the United States.

TikTok Secures U.S. Approval

Alongside tariff measures, Trump also signed an executive order formally approving a deal that allows TikTok to continue operating in the United States. According to Vice President JD Vance, the agreement values TikTok’s U.S. business at $14 billion.

Under the deal, a new joint venture will oversee TikTok’s U.S. operations. Chinese parent company ByteDance will hold less than 20% ownership, while American partners will control the majority stake. This structure was set as a condition for TikTok’s continued presence in the U.S. market, following years of political scrutiny and uncertainty.

Broader Implications

Analysts warn that the 100% tariff on branded pharmaceuticals could reshape industry dynamics in several ways:

• For Asian pharmaceutical firms:

  • Companies with significant U.S. revenue exposure face immediate headwinds.

  • Drug prices in the U.S. could rise, pressuring foreign firms to shift production stateside.

  • Capital investment may increasingly be redirected toward U.S.-based facilities

For U.S. consumers:

• The tariff could drive up the cost of imported specialty and patented medicines.

• Patients dependent on critical therapies from Asia may encounter higher expenses.

For U.S.–Asia trade relations:

• The measure risks sparking new friction with Japan, South Korea, and China.

• Asian governments may seek negotiations or retaliatory actions to safeguard domestic industries.

Meanwhile, the TikTok approval signals a more nuanced approach: Washington appears intent not only on imposing restrictions but also on asserting direct oversight over foreign platforms with significant influence in the U.S. digital landscape.

Trump’s tariff announcement has sent shockwaves through Asian equity markets, triggering steep losses in pharmaceutical stocks. While the long-term impact will depend on how many companies choose to establish manufacturing in the U.S. to secure exemptions, the move reaffirms the administration’s hardline “America First” trade posture.

At the same time, the TikTok decision highlights a dual-track strategy tightening control over foreign businesses while still allowing them to operate under strict conditions.

Global investors now face heightened uncertainty, closely monitoring both corporate responses and potential geopolitical fallout as Washington continues to recalibrate its trade and technology policies.